Sharechat Logo

Upside Biotechnologies wins $409k research grant, building closer ties with US Army

Tuesday 30th January 2018

Text too small?

Upside Biotechnologies, a regenerative tissue developer spun out of Auckland University, has won a $409,000 research grant to prepare its PelliCel product for a clinical trial and deepening its existing relationship with the US Army. 

Auckland-based Upside, which raised $2.3 million last year, won the Medical Technology Enterprise Consortium (MTEC) prototype acceleration award, it said in a statement. The biotech firm is developing an advanced skin replacement treatment for burn victims, enabling a small sample of unburnt skin to be grown in a lab and used as skin grafts for patients who don't have enough uninjured skin for a conventional graft. 

"Burns are a major issue for military personnel and Upside’s pioneering technology is designed to improve outcomes in those individuals who suffer from large burns," chief executive Robert Feldman said. "The award will support Upside Biotechnologies to ready its product, PelliCel, for a clinical trial." 

Last year, Upside signed a Cooperative Research and Development Agreement with US Army Medical Research and Materiel Command to collaborate on the scientific and regulatory sides of its technology. 

The New Zealand firm's investors include ICE Angels Nominees, which represent investment from both ICE Angels Individuals and Tuhua Ventures, Auckland Uniservices, Cure Kids Ventures, the New Zealand Venture Investment Fund, and Stephen Tindall's K One W One. 

(BusinessDesk)

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

MARKET CLOSE: NZ shares shrug off Synlait slump, join global rally
NZ dollar sticks to a tight range ahead of 2Q GDP data
NZ Shareholders' Assn elevates capital market concerns to PM
High Court orders reinvestigation of Chinese steel imports
Govt needs to consider ratepayer burden in 3 waters policy, Mahuta says
Heartland needs access to wholesale funding to grow Australian reverse mortgages
NZ annual current account deficit widest in nine years
Synlait Milk almost doubles annual profit on high value product growth
Consumer confidence falls to six-year low in September quarter
Near-record throughput at Marsden Point

IRG See IRG research reports